Global Institute Of Stem Cell Therapy And Research

Publications

What Sets Us Apart

Headquartered in U.S.A.
Founder is leading stem cell scientist credited with setting up the stem cell research programs at top research institutions in U.S.A. including Salk Research Institute, Sanford-Burnham Institute, UCI, UCSD.
Medical Advisory Board comprising of luminaries from Harvard, University of California, San Diego (UCSD), University of California Irvine (UCI), Imperial Collage, London
Endorsed by Honorable Prime Minister of India.
State of the art and only private hospital in India inaugrated by Prime Minister.
  1. Claudins and cancer: Fall of the soldiers entrusted to protect the gate and keep the barrier intact. Singh AB, Dhawan P. Semin Cell Dev Biol. 2015 May 27. pii: S1084-9521(15)00098-1. doi: 10.1016/j.semcdb.2015.05.001.
  2. Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. Bhat AA, Pope JL, Smith JJ, Ahmad R, Chen X, Washington MK, Beauchamp RD, Singh AB, Dhawan P. Oncogene. 2014 Dec 15. doi: 10.1038/onc.2014.385.
  3. Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenamatous polyposis coli-mediated colon tumorigenesis. Pope JL, Ahmad R, Bhat AA, Washington MK, Singh AB, Dhawan P. Mol Cancer. 2014 Jul 6;13:167. doi: 10.1186/1476-4598-13-167.
  4. Targeted colonic claudin-2 expression renders resistance to epithelial injury, induces immune suppression, and protects from colitis. Ahmad R, Chaturvedi R, Olivares-Villagómez D, Habib T, Asim M, Shivesh P, Polk DB, Wilson KT, Washington MK, Van Kaer L, Dhawan P, Singh AB. Mucosal Immunol. 2014 Nov;7(6):1340-53. doi: 10.1038/mi.2014.21. Epub 2014 Mar 26.
  5. Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Pope JL, Bhat AA, Sharma A, Ahmad R, Krishnan M, Washington MK, Beauchamp RD, Singh AB, Dhawan P. Gut. 2014 Apr;63(4):622-34. doi: 10.1136/gutjnl-2012-304241. Epub 2013 Jun 13.
  6. Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics. 30:2393-8 (2014).
  7. inigan JH, Vasu VT, Thaikoottathil JV, Mishra R, Shatat MA, Mason RJ, Kern JA. HER2 activation results in β-catenin-dependent changes in pulmonary epithelial permeability. Am J Physiol Lung Cell Mol Physiol. 2015 Jan 15;308(2):L199-207. doi: 10.1152/ajplung.00237.2014. Epub 2014 Oct 17.
  8. Embryonic Stem Cells in Medicinal Chemistry and Drug Development. Srivastava AS. Curr Top Med Chem. 2011 Mar 30.
  9. Artificial Hematopoietic Stem Cell Niche: Bioscaffolds to Microfluidics to Mathematical Simulations. Didwania M, Didwania A, Mehta G, Basak GW, Yasukawa S, Takayama S, de Necochea-Campion R, Srivastava A, Carrier E. Curr Top Med Chem. 2011 Mar 30.
  10. Cancer Stem Cells and Colorectal Cancer: An Overview. Dhawan P, Ahmad R, Srivastava AS, Singh AB. Curr Top Med Chem. 2011 Mar 30.
  11. Mitochondrial function controls proliferation and early differentiation potential of embryonic stem cells. Mandal S, Lindgren AG, Srivastava AS, Clark AT, Banerjee U. Stem Cells. 2011 Mar;29(3):486-95.
  12. Singh, U.P., Narendra P. Singh, Balwan Singh, Lorne J. Hofseth, Robert L Price, Mitzi Nagarkatti, and Prakash S. Nagarkatti.
    (2011) Role of resveratrol-induced CD11b+ Gr-1+ myeloid derived suppressor cells (MDSCs) in the reduction of CXCR3+ T cells and amelioration of chronic colitis in IL-10-/- mice. (Accepted in Brain, Behavior and Immunity).
  13. Singh, U.P.*, Narendra P. Singh*, Balwan Singh, Robert L Price, Mitzi Nagarkatti,and Prakash S. Nagarkatti.
    (2011) Activation of Aryl Hydrocarbon Receptor Leads to Reciprocal Epigenetic Regulation of FoxP3 and IL-17 genes and Amelioration of Experimental Colitis. (Accepted in PLoS ONE).
  14. Singh, U.P., Narendra P. Singh, Balwan Singh, Lorne J. Hofseth, Robert L Price,Mitzi Nagarkatti, and Prakash S. Nagarkatti (2010) Resveratrol (trans-3, 5, 4′- trihydroxystilbene) induces SIRT1 and down-regulates NF-kB activation toabrogate DSS-induced colitis. J. Pharmacology & Exp. Therapeutics. 332(3): 829-839.
  15. Xiangli Cui, Yu Jin, Anne B. Hofseth, Alexander Chumanevich, Mitzi Nagarkatti,Prakash S. Nagarkatti, Udai P. Singh, and Lorne J. Hofseth (2010) Resveratrolsuppresses colitis and colon cancer associated with colitis. Cancer-Prevention Research. 3(4): 549-559.
  16. Singh, U.P., Narendra P. Singh, Balwan Singh, Mishra Manoj, Mitzi Nagarkatti, Prakash S. Nagarkatti and Singh SR (2010) Stem cells as potential therapeutic targets for Inflammatory Bowel Disease. Frontiers in Biosciences S (2): 993-1008.
  17. Lorne J. Hofseth, Singh, U.P., Narendra P. Singh, Mitzi Nagarkatti, and Prakash S. Nagarkatti (2010) Taming the beast within: resveratrol suppresses colitis and prevents colon cancer. Aging 2(4): 183-184.
  18. Yu Jin, Xiangli Cui, Udai P. Singh, Brook Harmon, Philip Cavicchia, Anne B. Hofseth, Venkata Kotakadi, Brandy Stroud, Alexander A. Chumanevich,James R. Hebert, Thomas G. Hurley, and Lorne J. Hofseth (2010) Systemic inflammatory load in humans is suppressed by consumption of two formulations of dried, encapsulated juice concentrate. Molecular Nutrition and Food Research (54): 1-9.
  19. Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Jung AS, Holman PR, Castro JE, Carrier EK, Bashey A, Lane TA, Nelson CL, Pu M, Messer K, Corringham SM, Ball ED. Biol Blood Marrow Transplant. 2009 Oct;15(10):1306-13. Epub 2009 Aug 3.
  20. Human embryonic stem cells hemangioblast express HLA-antigens. Basak GW, Yasukawa S, Alfaro A, Halligan S, Srivastava AS, Min WP, Minev B, Carrier E. J Transl Med. 2009 Apr 22;7:27.
  21. Multiple myeloma bone marrow niche. Basak GW, Srivastava AS, Malhotra R, Carrier E. Curr Pharm Biotechnol. 2009 Apr;10(3):345-6. Review.
  22. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED. Blood. 2009 Feb 12;113(7):1581-8. Epub 2008 Oct 30.
  23. Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies. D’Orlans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, Simard E. Vascul Pharmacol. 2008 Aug-Sep;49(2-3):51-62. Epub 2008 Jul 12. Review.
  24. Singh U.P., Singh, R., Singh, S., Karls R.K., Quinn F.D., Taub, D.D., and J.W. Lillard, Jr. (2008) CXCL10+ T cells and NK cells assist in the recruitment and activation of CXCR3+ and CXCL11+ leukocytes during Mycobacteria-enhanced colitis. BMC Immunol. 9(1): 25.
  25. Singh U.P.*, Sakthivel, S.K.*, Singh, S., Taub, D.D., Igietseme, J.U., and J.W. Lillard, Jr. (2008) CCL5 regulation of mucosal chlamydial immunity and infection. BMC Microbiol. 8:136.
  26. Singh U.P.*, Sakthivel, S.K.*, Singh, S., Taub, D.D., Kristian R Novakovic, and J.W. Lillard, Jr. (2008) CXCL10-blockade protects mice from cyclophosphamide- induced cystitis. J immune Based Ther Vaccines. 6(1): 6.
  27. Singh U.P., Singh, S., Singh, R., Cong, Y., Taub, D.D. and J.W. Lillard, Jr. (2008) Chronic colitis and CXCL10-producing mucosal T helper, NK and NKT cells in IL10-/- mice can be abrogated by CXCL10 blockade. Journal of Interferon and Cytokine Research. 28(1): 31-43.
  28. Singh U.P., A. Krishna, and Kunwar P. Bhatnagar (2008) Changes in serum leptin, insulin, androstenedione, and luteinizing hormone during ovarian cycle in the bat, Taphozous longimanus. Acta Biologica Hungarica. 59(1): 1-16.* Indicate equal contribution
  29. Prospects of embryonic stem cells in treatment of hematopoietic disorders. Srivastava AS, Malhotra R, Esmaeli-Azad B, Lane T, Carrier E. Curr Pharm Biotechnol. 2007 Oct;8(5):305-17. Review.
  30. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA. Transfusion. 2007 Nov;47(11):2153-60.
  31. Ovarian recovery after stem cell transplantation. Liu J, Malhotra R, Voltarelli J, Stracieri AB, Oliveira L, Simoes BP, Ball ED, Carrier E. Bone Marrow Transplant. 2008 Feb;41(3):275-8. Epub 2007 Oct 22.
  32. Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/- KO mice. Srivastava AS, Feng Z, Mishra R, Malhotra R, Kim HS, Carrier E. Biochem Biophys Res Commun. 2007 Oct 5;361(4):953-9. Epub 2007 Aug 1.
  33. Thrombopoietin enhances generation of CD34+ cells from human embryonic stem cells. Srivastava AS, Nedelcu E, Esmaeli-Azad B, Mishra R, Carrier E. Stem Cells. 2007 Jun;25(6):1456-61. Epub 2007 Mar 22.
  34. Singh U.P., Singh S, Chandrasekar Venkataraman and James W. Lillard, Jr. (2007) CXCR3 Axis: Role in Inflammatory Bowel Disease and its Therapeutic Implication. Endocrine, Metabolic & Immune Disorder: Drug Target. 7(2): 111- 123.
  35. Singh U.P., Singh S, Singh R, Frederick D. Quinn, Morris E. Potter & James W. Lillard, Jr. (2007) Influence of Mycobacterium avium paratuberculosis on colitis development and specifics immune responses during disease. Infection and Immunity. 75 (8): 3722-3278.
  36. Dexamethasone facilitates erythropoiesis in murine embryonic stem cells differentiating into hematopoietic cells in vitro. Srivastava AS, Kaushal S, Mishra R, Lane TA, Carrier E. Biochem Biophys Res Commun. 2006 Jul 28;346(2):508-16. Epub 2006 Jun 2.
  37. Transplanted embryonic stem cells successfully survive, proliferate, and migrate to damaged regions of the mouse brain. Srivastava AS, Shenouda S, Mishra R, Carrier E. Stem Cells. 2006 Jul;24(7):1689-94. Epub 2006 Mar 30.
  38. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA, Hassidim K, Ball ED. Leuk Res. 2006 Apr;30(4):503-6. Epub 2005 Nov 21.
  39. Improving the efficiency of PBPC collection by pre-apheresis peripheral blood and mid-apheresis product measurements of CD34 cells. Lane TA, Bashey A, Carrier E, Holman P, Castro J, Mullen M, Ward DM, Ada O, Ball ED. Cytotherapy. 2004;6(4):318-27.
  40. In utero DNA immunisation. Immunity over tolerance in fetal life. Rizzi M, Gerloni M, Srivastava AS, Wheeler MC, Schuler K, Carrier E, Zanetti M. Vaccine. 2005 Jul 21;23(33):4273-82.
  41. Hematopoietic stem cell transplantation for multiple sclerosis. Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R. Arch Neurol. 2005 Jun;62(6):860-4. Review.
  42. In utero gene therapy: prospect and future. Chauhan DP, Srivastava AS, Moustafa ME, Shenouda S, Carrier E. Curr Pharm Des. 2004;10(29):3663-72. Review.
  43. Chimerism and tolerance post-in utero transplantation with embryonic stem cells. Moustafa ME, Srivastava AS, Nedelcu E, Donahue J, Gueorguieva I, Shenouda SS, Minev B, Carrier E. Transplantation. 2004 Nov 15;78(9):1274-82.
  44. T-cell depletion improves outcome after autologous stem cell transplant in patients with systemic lupus erythematosus (SLE). Kamrava MR, Anderson EM, Kalunian K, Bashey A, Holman P, Medina B, Ball ED, Carrier E. Bone Marrow Transplant. 2005 Jan;35(2):205-6. No abstract available. Erratum in: Bone Marrow Transplant. 2005 Feb;35(3):321.
  45. A regulatory role of Wnt signaling pathway in the hematopoietic differentiation of murine embryonic stem cells. Feng Z, Srivastava AS, Mishra R, Carrier E. Biochem Biophys Res Commun. 2004 Nov 26;324(4):1333-9.
  46. In utero detection of T7 phage after systemic administration to pregnant mice. Srivastava AS, Chauhan DP, Carrier E. Biotechniques. 2004 Jul;37(1):81-3.
  47. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma. Wang EH, Chen YA, Corringham S, Bashey A, Holman P, Ball ED, Carrier E. Bone Marrow Transplant. 2004 Oct;34(7):581-7.
  48. Induction of apoptosis in human lung cancer cells by curcumin. Radhakrishna Pillai G, Srivastava AS, Hassanein TI, Chauhan DP, Carrier E. Cancer Lett. 2004 May 28;208(2):163-70.
  49. Purification and properties of cytosolic alanine aminotransferase from the liver of two freshwater fish, Clarias batrachus and Labeo rohita. Srivastava AS, Oohara I, Suzuki T, Shenouda S, Singh SN, Chauhan DP, Carrier E. Comp Biochem Physiol B Biochem Mol Biol. 2004 Feb;137(2):197-207.
  50. Immunological factors that affect the in vivo fate of T7 phage in the mouse. Srivastava AS, Kaido T, Carrier E. J Virol Methods. 2004 Jan;115(1):99-104.
  51. Singh U.P., S. Singh, R. Palaniappan, D.D. Taub, and J.W. Lillard, Jr. (2004) vMIP-II versus I-309 effects on adaptive immunity. Journal of Immunology 173:5509-5516.
  52. Singh U.P., Singh S., Boyaka, P.N., McGhee, J.R., and Lillard, J.R. (2004) Granulocyte chemotactic protein-2 mediates adaptive immunity through CXCR1 interactions and CD28/B7 upregulation. Journal of Leukocyte Biology. 76:1240- 1247.
  53. FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia. Tanner ML, Hoh CK, Bashey A, Holman P, Sun C, Broome HE, Lane T, Ball ED, Carrier E. Bone Marrow Transplant. 2003 Sep;32(6):581-5.
  54. Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus. Burt RK, Marmont A, Arnold R, Heipe F, Firestein GS, Carrier E, Hahn B, Barr W, Oyama Y, Snowden J, Kalunian K, Traynor A. Bone Marrow Transplant. 2003 Aug;32 Suppl 1:S49-51.
  55. Tolerance and immunity following in utero transplantation of allogeneic fetal liver cells: the cytokine shift. Sefrioui H, Donahue J, Gilpin EA, Srivastava AS, Carrier E. Cell Transplant. 2003;12(1):75-82.
  56. Lillard, Jr., J. W., U.P. Singh, P.N. Boyaka, S. Singh, D.D. Taub and J.R. McGhee (2003) MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood.101: 807-814.
  57. Singh U.P., S. Singh, D.D. Taub, and J.W. Lillard, Jr. (2003) Inhibition of IP-10 abrogates colitis in IL-10-/- mice. Journal of Immunology.171: 1401-1406.
  58. Singh U.P., S. Singh, D.D. Taub, and J.W. Lillard, Jr. (2003) Interferon-inducible chemokines differentially mediate adaptive immunity and colitis. Journal of Interferon & Cytokine Research.23(10): 591-600.
  59. Alloreactivity following in utero transplantation of cytokine-stimulated hematopoietic stem cells: the role of recipient CD4(-) cells. Sefrioui H, Donahue J, Srivastava AS, Gilpin E, Lee TH, Carrier E. Exp Hematol. 2002 Jun;30(6):617-24.
  60. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation. Bashey A, Corringham S, Gilpin E, Fields KK, Smilee RC, DeFrancisco C, Santos-Ada O, Holman P, Carrier E, Ho AD, Lane TA, Ball ED, Janssen WE, Law P. Cytotherapy. 2000;2(3):195-200.
  61. Murine Sca-1(+)/Lin(-) cells and human KG1a cells exhibit multiple pseudopod morphologies during migration. Francis K, Palsson B, Donahue J, Fong S, Carrier E. Exp Hematol. 2002 May;30(5):460-3.
  62. Non-myeloablative transplants for congenital diseases. Donahue J, Carrier E. Cancer Treat Res. 2002;110:177-211. Review.
  63. Beneficial effect of intravenous lidocaine in cutaneous chronic graft-versus-host disease secondary to donor lymphocyte infusion. Voltarelli JC, Ahmed H, Paton EJ, Stracieri AB, Holman P, Bashey A, Coutinho M, Simoes BP, Ball ED, Carrier E. Bone Marrow Transplant. 2001 Jul;28(1):97-9.
  64. Postnatal cytokines and boosts improve chimerism and hematological parameters in beta-thalassemic mice transplanted in utero. Donahue J, Gilpin E, Young D, Carrier E. Transplantation. 2001 May 27;71(10):1491-4.
  65. Microchimerism does not induce tolerance and sustains immunity after in utero transplantation. Donahue J, Gilpin E, Lee TH, Busch MP, Croft M, Carrier E. Transplantation. 2001 Feb 15;71(3):359-68.
  66. Microchimerism does not induce tolerance after in utero transplantation and may lead to the development of alloreactivity. Carrier E, Gilpin E, Lee TH, Busch MP, Zanetti M. J Lab Clin Med. 2000 Sep;136(3):224-35.
  67. AB035673 Paralichthys olivaceus ppsb mRNA for pancreatic protein with two somatomedin B domains, complete cds gi|6561906|dbj|AB035673.1|[6561906]
  68. AB029757 Paralichthys olivaceus mRNA for elastase 3 precursor, complete cds gi|6815046|dbj|AB029757.2|[6815046]
  69. AB029752 Paralichthys olivaceus mRNA for trypsinogen 3, complete cds gi|6815044|dbj|AB029752.2|[6815044]
  70. AB029758 Paralichthys olivaceus mRNA for elastase 4 precursor, partial cds gi|5441868|dbj|AB029758.1|[5441868]
  71. AB029756 Paralichthys olivaceus mRNA for elastase 2 precursor, partial cds gi|5441864|dbj|AB029756.1|[5441864]
  72. AB029755 Paralichthys olivaceus mRNA for elastase 1 precursor, complete cds gi|5441862|dbj|AB029755.1|[5441862]
  73. AB029754 Paralichthys olivaceus mRNA for chymotrypsinogen 2, complete cds gi|5441860|dbj|AB029754.1|[5441860]
  74. AB029753 Paralichthys olivaceus mRNA for chymotrypsinogen 1, complete cds gi|5441858|dbj|AB029753.1|[5441858]
  75. AB029751 Paralichthys olivaceus mRNA for trypsinogen 2, partial cds gi|5441854|dbj|AB029751.1|[5441854]
  76. AB029750 Paralichthys olivaceus mRNA for trypsinogen 1, complete cds gi|5441852|dbj|AB029750.1|[5441852]
  77. AB196515 Paralichthys olivaceus COL1A3 mRNA for type 1 collagen alpha 3, partial cds gi|56565284|dbj|AB196515.1|[56565284]
  78. AB196514 Paralichthys olivaceus COL1A2 mRNA for type 1 collagen alpha 2, complete cds gi|56565282|dbj|AB196514.1|[56565282]
  79. AB196513 Paralichthys olivaceus COL1A1 mRNA for type 1 collagen alpha 1, complete cds gi|56565280|dbj|AB196513.1|[56565280]
  80. AB196517 Paralichthys olivaceus COL1A3 gene for type 1 collagen alpha 3, promoter region gi|56565287|dbj|AB196517.1|[56565287]
  81. AB196516 Paralichthys olivaceus COL1A1 gene for type 1 collagen alpha 1, promoter region gi|56565286|dbj|AB196516.1|[56565286]
  82. AB099302 Paralichthys olivaceus CPB mRNA for carboxypeptidase B, partial cds gi|27529695|dbj|AB099302.1|[27529695]
  83. AB099301 Paralichthys olivaceus CPA1 mRNA for carboxypeptidase A1, partial cds gi|27529693|dbj|AB099301.1|[27529693]
  84. AB099300 Paralichthys olivaceus CPA2 mRNA for carboxypeptidase A2, complete cds gi|27529691|dbj|AB099300.1|[27529691]
  85. AB049616 Paralichthys olivaceus mRNA for keratin, partial cds gi|10716083|dbj|AB049616.1|[10716083]
  86. AB037674 Paralichthys olivaceus VDRa mRNA for vitamin D receptor a, complete cds gi|7670337|dbj|AB037674.1|[7670337]
  87. AB037673 Paralichthys olivaceus VDRb mRNA for vitamin D receptor b, complete cds gi|7670328|dbj|AB037673.1|[7670328]
  88. Recruitment of engrafted donor cells postnatally into the blood with cytokines after in utero transplantation in mice. Carrier E, Lee TH, Busch MP, Cowan MJ. Transplantation. 1997 Aug 27;64(4):627-33.
  89. The exicting life of Elisabeth Carrier, nurse without borders. Interview by Sylvie Vallieres. Carrier E. Infirm Que. 1997 Mar-Apr;4(4):38-9.
  90. Induction of tolerance in nondefective mice after in utero transplantation of major histocompatibility complex-mismatched fetal hematopoietic stem cells. Carrier E, Lee TH, Busch MP, Cowan MJ. Blood. 1995 Dec 15;86(12):4681-90.
  91. Glucocorticoid receptors in lymphocytes in anorexia nervosa. Girardin E, Garoscio-Cholet M, Dechaud H, Lejeune H, Carrier E, Tourniaire J, Pugeat M. Clin Endocrinol (Oxf). 1991 Jul;35(1):79-84.
  92. Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment. Horning SJ, Carrier EK, Rouse RV, Warnke RA, Michie SA. J Clin Oncol. 1989 Sep;7(9):1281-7.
WordPress Video Lightbox